Time slot's time in Taipei (GMT+8)
2025/11/22 12:40-13:30 Room 101 AB
- Lunch Symposium-美時化學製藥股份有限公司 Lotus.
美時化學製藥股份有限公司 Lotus.
- Time
- Topic
- Speaker
- Moderator
- 12:40-13:30
- Entacapone Clinical Benefit beyond Motor fluctuations
- Speaker:
Yi-Cheng Tai
(Taiwan)
- Moderator:
Yueh-Feng Sung
(Taiwan)
- Yi-Cheng Tai
Lecture Abstract：
Entacapone has been widely used in the treatment of moderate to advanced Parkinson’s disease (PD), and its efficacy for motor symptoms has been well-known from several clinical trials and long-term clinical use. The efficacy of Levodopa/Carbidopa/Entacapone (LCE) on neuropsychological functions in moderate to advanced PD has not been validated yet, and little is known about the effect of LCE on peripheral inflammatory cytokines.
May talk on this lecture will going to share 2025 BMC neurology article regarding LCE treatment significantly influenced ΔIL-6 levels, whereas DAs usage had no significant influence on the ΔIL-6 levels. When levodopa is metabolized in the body, it follows two main pathways: conversion to dopamine through the dopa decarboxylase (DDC) pathway
and conversion to 3-oxygen-methyldopa (3-OMD) via the COMT pathway. Traditional compounded levodopa preparations only inhibit the DDC pathway, which blocks the metabolism of peripheral levodopa to dopamine but lacks inhibition of the COMT pathway
. LCE is a compounded dopaminergic agent that inhibits both the DDC and COMT pathways, improving the bioavailability of levodopa and effectively prolonging the “on” period in PD patients, thereby improving motor symptoms
Entacapone has been widely used in the treatment of moderate to advanced Parkinson’s disease (PD), and its efficacy for motor symptoms has been well-known from several clinical trials and long-term clinical use. The efficacy of Levodopa/Carbidopa/Entacapone (LCE) on neuropsychological functions in moderate to advanced PD has not been validated yet, and little is known about the effect of LCE on peripheral inflammatory cytokines.
May talk on this lecture will going to share 2025 BMC neurology article regarding LCE treatment significantly influenced ΔIL-6 levels, whereas DAs usage had no significant influence on the ΔIL-6 levels. When levodopa is metabolized in the body, it follows two main pathways: conversion to dopamine through the dopa decarboxylase (DDC) pathway
and conversion to 3-oxygen-methyldopa (3-OMD) via the COMT pathway. Traditional compounded levodopa preparations only inhibit the DDC pathway, which blocks the metabolism of peripheral levodopa to dopamine but lacks inhibition of the COMT pathway
. LCE is a compounded dopaminergic agent that inhibits both the DDC and COMT pathways, improving the bioavailability of levodopa and effectively prolonging the “on” period in PD patients, thereby improving motor symptoms
